DelveInsight’s “EGFR-Non Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the EGFR-Non Small Cell Lung Cancer, historical and forecasted epidemiology as well as the EGFR-Non Small Cell Lung Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the EGFR-Non Small Cell Lung Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; EGFR-Non Small Cell Lung Cancer Market Forecast
Some of the key facts of the EGFR-Non Small Cell Lung Cancer Market Report:
- The EGFR-Non Small Cell Lung Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- In October 2023, Janssen, a subsidiary of Johnson & Johnson based in Belgium, has released results from the Phase III MARIPOSA-2 clinical study of Rybrevant (amivantamab-vmjw) regimens in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). This randomized trial, conducted in an open-label fashion, evaluated the safety and effectiveness of two different treatment protocols involving Rybrevant in combination with chemotherapy, with and without lazertinib.
- In September 2023, The Janssen Pharmaceutical Companies, a division of Johnson & Johnson, have released positive initial findings from the Phase 3 MARIPOSA trial assessing RYBREVANT® (amivantamab-vmjw), a bispecific antibody targeting the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), when used alongside lazertinib, an oral third-generation EGFR tyrosine kinase inhibitor (TKI), compared to osimertinib as the first-line therapy for patients diagnosed with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).
- Among the European 5 countries, Germany had the highest cases of NSCLC. Furthermore, Japan accounts for about 117,752 cases in 2020
- DelveInsight’s analysts have estimated that in 2020, in the United States there were over 38,000 incident cases for EGFR mutation.
- The highest number of Non Small Cell Lung Cancer were estimated in the United States
- Key EGFR-Non Small Cell Lung Cancer Companies: Abbvie, Yuhan Corporation, Janssen Research & Development), Novartis, Daiichi Sankyo, and others
- Key EGFR-Non Small Cell Lung Cancer Therapies: Telisotuzumab Vedotin(Teliso-V), Lazertinib (Leclaza), Nazartinib (EGF816), Patritumab deruxtecan (HER3-DXd), and others
- The EGFR-NSCLC epidemiology based on gender analyzed that in the United States, 7 out of 10 patients had metastatic NSCLC (Stage III b and IV)
- The EGFR-Non Small Cell Lung Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage EGFR-Non Small Cell Lung Cancer pipeline products will significantly revolutionize the EGFR-Non Small Cell Lung Cancer market dynamics.
EGFR-Non Small Cell Lung Cancer Overview
There are mainly two types of lung cancer small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adeno squamous carcinomas, and sarcomatoid carcinomas.
Get a Free sample for the EGFR-Non Small Cell Lung Cancer Market Report –
EGFR-Non Small Cell Lung Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
EGFR-Non Small Cell Lung Cancer Epidemiology Segmentation:
The EGFR-Non Small Cell Lung Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of EGFR-Non Small Cell Lung Cancer
- Prevalent Cases of EGFR-Non Small Cell Lung Cancer by severity
- Gender-specific Prevalence of EGFR-Non Small Cell Lung Cancer
- Diagnosed Cases of Episodic and Chronic EGFR-Non Small Cell Lung Cancer
Download the report to understand which factors are driving EGFR-Non Small Cell Lung Cancer epidemiology trends @ EGFR-Non Small Cell Lung Cancer Epidemiology Forecast
EGFR-Non Small Cell Lung Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the EGFR-Non Small Cell Lung Cancer market or expected to get launched during the study period. The analysis covers EGFR-Non Small Cell Lung Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the EGFR-Non Small Cell Lung Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
EGFR-Non Small Cell Lung Cancer Therapies and Key Companies
- Telisotuzumab Vedotin(Teliso-V): Abbvie
- Lazertinib (Leclaza): Yuhan Corporation/ Janssen Research & Development)
- Nazartinib (EGF816): Novartis
- Patritumab deruxtecan (HER3-DXd): Daiichi Sankyo
Discover more about therapies set to grab major EGFR-Non Small Cell Lung Cancer market share @ EGFR-Non Small Cell Lung Cancer Treatment Market
EGFR-Non Small Cell Lung Cancer Market Drivers
- Increasing Use of Biomarker Testing
- Increase in the Mutation Specific Trials Activity and Approval
- Increasing Incidence of NSCLC
- Rich Pipeline and label expansion of approved therapies
EGFR-Non Small Cell Lung Cancer Market Barriers
- Cost-Effectiveness of Therapies
- Small Patient Populations for Specific Subsets of NSCLC
- Generic or Biosimilar Erosion
Scope of the EGFR-Non Small Cell Lung Cancer Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key EGFR-Non Small Cell Lung Cancer Companies: Abbvie, Yuhan Corporation, Janssen Research & Development), Novartis, Daiichi Sankyo, and others
- Key EGFR-Non Small Cell Lung Cancer Therapies: Telisotuzumab Vedotin(Teliso-V), Lazertinib (Leclaza), Nazartinib (EGF816), Patritumab deruxtecan (HER3-DXd), and others
- EGFR-Non Small Cell Lung Cancer Therapeutic Assessment: EGFR-Non Small Cell Lung Cancer current marketed and EGFR-Non Small Cell Lung Cancer emerging therapies
- EGFR-Non Small Cell Lung Cancer Market Dynamics: EGFR-Non Small Cell Lung Cancer market drivers and EGFR-Non Small Cell Lung Cancer market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- EGFR-Non Small Cell Lung Cancer Unmet Needs, KOL’s views, Analyst’s views, EGFR-Non Small Cell Lung Cancer Market Access and Reimbursement
To know more about EGFR-Non Small Cell Lung Cancer companies working in the treatment market, visit @ EGFR-NSCLC Clinical Trials and Therapeutic Assessment
Table of Contents
1. EGFR-Non Small Cell Lung Cancer Market Report Introduction
2. Executive Summary for EGFR-Non Small Cell Lung Cancer
3. SWOT analysis of EGFR-Non Small Cell Lung Cancer
4. EGFR-Non Small Cell Lung Cancer Patient Share (%) Overview at a Glance
5. EGFR-Non Small Cell Lung Cancer Market Overview at a Glance
6. EGFR-Non Small Cell Lung Cancer Disease Background and Overview
7. EGFR-Non Small Cell Lung Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of EGFR-Non Small Cell Lung Cancer
9. EGFR-Non Small Cell Lung Cancer Current Treatment and Medical Practices
10. EGFR-Non Small Cell Lung Cancer Unmet Needs
11. EGFR-Non Small Cell Lung Cancer Emerging Therapies
12. EGFR-Non Small Cell Lung Cancer Market Outlook
13. Country-Wise EGFR-Non Small Cell Lung Cancer Market Analysis (2019–2032)
14. EGFR-Non Small Cell Lung Cancer Market Access and Reimbursement of Therapies
15. EGFR-Non Small Cell Lung Cancer Market Drivers
16. EGFR-Non Small Cell Lung Cancer Market Barriers
17. EGFR-Non Small Cell Lung Cancer Appendix
18. EGFR-Non Small Cell Lung Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/